Rebound rates are around the same in people who took the drug and those who didn't, according to a new FDA study.
— it was a major talking point around the drug. This new report offers data to counterbalance those anecdotal reports.Pfizer, which makes Paxlovid, said it's running two additional studies to try and understand symptom rebound.
The info was part of the FDA's briefing document ahead of a meeting of the agency's advisors Thursday, where they'll discuss whether the FDA should fully approve Paxlovid. The drug is currently available because of the FDA's emergency use authorization.Picture Alliance/DPA via Getty Images
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA: Paxlovid Does Not Cause COVID ‘Rebound’The FDA says in a new report that rebound also occurs in people who did not take paxlovid—which can prevent COVID from becoming severe if given early enough—and appears to be part of the disease process in some.
Read more »
FDA: Paxlovid not associated with COVID reboundPaxlovid isn't associated with COVID rebound, in which patients test positive or have symptoms days after a course of the drug is completed, Food and Drug Administration staff said Tuesday.
Read more »
FDA authorizes Pfizer's Covid omicron booster as fourth shot for kids under 5The FDA authorized Pfizer's omicron booster shot for kids younger than five who were previously vaccinated with three doses of the company's original shot.
Read more »
FDA Staff Report Says Data Shows Pfizer's Covid Treatment Paxlovid Is Effective in High-Risk AdultsFDA staff said Pfizer’s clinical trial results on its Covid antiviral pill Paxlovid support its use in adults at high risk of progressing to severe disease.
Read more »
USD/JPY kisses the 134.00 mark on a rebound ahead of US CPIUSD/JPY rebounded after hitting the monthly low of 132.34. The short covering just comes ahead of the US Consumer Price Index (CPI) release. The corre
Read more »
Futures steady as banks rebound; inflation data on tap By Reuters*U.S. STOCK FUTURES RISE AFTER BANK ROUT, CPI DATA AWAITED $DIA $SPY $QQQ 🇺🇸🇺🇸
Read more »